Abstract
Plasma products are used to treat a number of serious inherited disorders, of which the best known is haemophilia. However, a number of other conditions exist at a similar frequency in the population but are much less well known: Alpha 1-Antitrypsin (AAT) deficiency or ‘Alpha-1’ is one of these. Alpha-1 is a life-threatening genetic disorder in some individuals who demonstrate clinical evidence of emphysema. Left untreated, this form of emphysema can be fatal. Historically, people with Alpha-1 have been concerned with the critical short supply of the therapy. Recent product approvals will provide the desperately needed product, so people with Alpha-1 can focus more on their lives and less on when their therapy will be available.
Get full access to this article
View all access options for this article.